Compare GOVX & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOVX | ICCM |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.6M |
| IPO Year | 1996 | 2013 |
| Metric | GOVX | ICCM |
|---|---|---|
| Price | $0.14 | $0.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $10.00 | ★ $22.67 |
| AVG Volume (30 Days) | ★ 131.4K | 87.3K |
| Earning Date | 11-20-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,489,145.00 | N/A |
| Revenue This Year | N/A | $27.11 |
| Revenue Next Year | N/A | $104.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.14 | $0.13 |
| 52 Week High | $1,299.75 | $9.54 |
| Indicator | GOVX | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 9.71 | 31.20 |
| Support Level | N/A | $0.22 |
| Resistance Level | $4.60 | $2.50 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 0.94 | 36.17 |
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.